Moderna Fellowships
Moderna, in collaboration with MCPHS, offers a unique opportunity for PharmD graduates to gain rapid experience in the pharmaceutical industry. Overall, this fellowship program will provide the training and experiences necessary to prepare the fellow for a career in a competitive pharmaceutical industry. Moderna will be recruiting 3 fellows for the fellowship programs starting in July 2025.
The fellowship programs are:
- Global Regulatory Science: 1 position
- Clinical Safety and Pharmacovigilance: 1 position
- Clinical Development Operations: 1 position
Please see our brochure for additional details.
If you have any questions, please contact us at pharmd.fellowships@modernatx.com.
About Moderna
Moderna is a leader in the creation of the field of messenger RNA (mRNA) medicine. By working at the intersection of science, technology and health for more than a decade, we have developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
Our mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, we strive to deliver the greatest possible impact to people through mRNA medicines.
Our first commercial product, Spikevax (our COVID-19 vaccine), has helped hundreds of millions of people worldwide combat COVID-19. SARS-CoV-2, the virus that causes COVID-19, continues to evolve and in 2023, the COVID-19 vaccine market transitioned to an endemic, seasonal commercial market. Our second commercial product, mRESVIA, an RSV vaccine, was approved by the FDA in May 2024.
Having demonstrated clinical benefit in multiple infectious disease areas and skin cancer, as well as potential clinical benefit for several rare genetic diseases, we continue to advance a broad and diverse pipeline and are focused on execution to deliver for patients. Our pipeline includes 47 therapeutic and vaccine programs, nine of which are in late-stage development.
To learn more, visit www.modernatx.com.